Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis
= 0.0002). The most usual extrapyramidal symptom was akathisia. Brexpiprazole 2-4 mg showed significant improvements in PANSS and CGI-S scores, with a lower risk of treatment discontinuation. These findings support its efficacy and tolerability in managing schizophrenia.
Authors
- Muhammad Bilal Akbar (ORCID: https://orcid.org/0000-0001-6314-3445)
- Abdul Haseeb Mohammed
- Sadikun Nabi
- Saliha Saad (ORCID: https://orcid.org/0000-0002-4436-7053)
- Ismailova Rushana Nurbekovna
- Hiba Manaf
- Sher Bano
- Aashan Ahmad
- SIDRA HARISS
- Farah Saleh
- Noor Fatima
- Raouf Khan (ORCID: https://orcid.org/0009-0008-0794-8888)
- Zainab Salahuddin
- Laiba Ajmal
Institutions
- University of Jordan (JO)
- Jordan University of Science and Technology (JO)
- Comilla Medical College (BD)
- Jordan Hospital (JO)
- Combined Military Hospital (PK)
- Montgomery High School (US)
- Tallaght University Hospital (IE)
- Shaheed Zulfiqar Ali Bhutto Institute of Science and Technology (PK)
- Shifa Tameer-e-Millat University (PK)
- Thumbay Group (United Arab Emirates) (AE)
- Tashkent Pediatric Medical Institute (UZ)
- Pakistan Institute of Medical Sciences (PK)
- Westminster International University in Tashkent (UZ)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences Reports
- Published
- 2026-04-12
- DOI
- https://doi.org/10.1002/pcn5.70332
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00